Table S1: Current published guidelines for indication for SLK transplantation in patients with hepatic cirrhosis.

| Eason et al. (2008)(1) | 1. End-stage renal disease  
2. CKD with GFR ≤ 30 mL/min  
3. AKI/HRS with Serum creatinine ≥ 2 mg/dL or dialysis ≥ 8 weeks  
4. CKD and kidney biopsy > 30% glomerulosclerosis or 30% fibrosis. |
|------------------------|------------------------------------------------------------------|
| OPTN Policy 3.5.10 (2009) | 1. CKD requiring dialysis  
2. CKD and proteinuria >3 g/day  
3. Sustained AKI requiring dialysis for 6 weeks or more  
4. Sustained AKI (GFR ≤ 25 mL/min) for 6 weeks or more  
5. Sustained AKI: combination of categories (c)&(d) for a total of 6 Ws  
6. Metabolic disease |
| Nadim et al (2012)(2) | 1. Persistent AKI for ≥ 4 weeks with one of the of the following:  
   a. Stage 3 AKI (3 fold increase in serum creatinine, serum creatinine ≥4 mg/dl with an acute increase of ≥ 0.5 mg/dl) or RRT  
   b. eGFR ≤ 35 mL/min (MDRD 6 equation) or iGFR ≤ 25 mL/min  
2. Candidates with CKD for 3 month with one of the following  
   a. eGFR ≤ 40 mL/min (MDRD-6 equation) or iGFR ≤ 30 mL/min  
   b. Proteinuria > 2 g/day  
   c. ≥ 30% global glomerulosclerosis or ≥ 30% interstitial fibrosis  
   d. Metabolic disease. |